A blog post of Y Combinator says that it has launched YC Bio that focuses to fund early-stage life science companies that are still in the lab phase.
The first area of focus would be health span and age-related disease. It has also launched a special track like YC AI, in which the companies will go through the regular YC batch, but there will be a few differences.
Instead of the standard deal for YC companies (which is $120,000 invested for 7% ownership), they’ll offer these companies any amount between $500k and $1 million for 10-20% ownership, scaling linearly.
They will also offer the companies free lab space and in addition, have a number of other special deals for YC bio companies, and access to a wide range of experts.
There will be a specific RFS in our application system for companies to indicate they’re interested in this system. Other bio companies can apply for the standard YC program.
